NASDAQ:DSCI - Derma Sciences Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$7.00 0.00 (0.00 %)
(As of 10/23/2018 04:00 PM ET)
Previous Close$7.00
Today's Range$7.00 - $7.00
52-Week Range$2.92 - $7.05
VolumeN/A
Average Volume719,592 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Derma Sciences, Inc. (Derma Sciences) is a medical device company. The Company operates through two segments: advanced wound care and traditional wound care products. Advanced wound care products principally consist of both novel and otherwise differentiated dressings, devices and skin substitutes designed to promote wound healing and/or prevent infection. The Company's advanced wound care product line consists of MEDIHONEY, TCC-EZ, AMNIOEXCEL and AMNIOMATRIX, XTRASORB and BIOGUARD. Traditional wound care products principally consist of commodity related dressings, ointments, gauze bandages, adhesive bandages, wound closure strips, catheter fasteners and skin care products. The Company's traditional wound care product line includes branded gauze sponges and bandages, non-adherent impregnated dressings, retention devices, paste bandages and other compression devices for the medical markets.

Receive DSCI News and Ratings via Email

Sign-up to receive the latest news and ratings for DSCI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry N/A
Sub-IndustryHealth Care Supplies
SectorN/A
Current SymbolNASDAQ:DSCI
Previous Symbol
CUSIP24982750
Phone+1-609-5144744

Debt

Debt-to-Equity RatioN/A
Current Ratio1.29
Quick Ratio1.02

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins-20.97%
Return on Equity-17.10%
Return on Assets-12.43%

Miscellaneous

Employees263
Outstanding Shares28,340,000
Market Cap$0.00
OptionableN/A

Derma Sciences (NASDAQ:DSCI) Frequently Asked Questions

What is Derma Sciences' stock symbol?

Derma Sciences trades on the NASDAQ under the ticker symbol "DSCI."

How were Derma Sciences' earnings last quarter?

Derma Sciences Inc (NASDAQ:DSCI) released its quarterly earnings data on Tuesday, August, 9th. The medical instruments supplier reported $0.08 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.08) by $0.16. The medical instruments supplier had revenue of $22.20 million for the quarter, compared to analysts' expectations of $22.40 million. Derma Sciences had a negative return on equity of 17.10% and a negative net margin of 20.97%. View Derma Sciences' Earnings History.

How do I buy shares of Derma Sciences?

Shares of DSCI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Derma Sciences' stock price today?

One share of DSCI stock can currently be purchased for approximately $7.00.

What is Derma Sciences' official website?

The official website for Derma Sciences is http://www.dermasciences.com/.

How can I contact Derma Sciences?

Derma Sciences' mailing address is 214 Carnegie Ctr Ste 300, PRINCETON, NJ 08540-6237, United States. The medical instruments supplier can be reached via phone at +1-609-5144744.


MarketBeat Community Rating for Derma Sciences (NASDAQ DSCI)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  208 (Vote Outperform)
Underperform Votes:  147 (Vote Underperform)
Total Votes:  355
MarketBeat's community ratings are surveys of what our community members think about Derma Sciences and other stocks. Vote "Outperform" if you believe DSCI will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DSCI will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel